A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Vixotrigine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms RELAY-1
- Sponsors Biogen; Convergence Pharmaceuticals
- 21 Mar 2018 Planned End Date changed from 22 Aug 2018 to 2 Aug 2018.
- 21 Mar 2018 Planned primary completion date changed from 22 Aug 2018 to 2 Aug 2018.
- 21 Mar 2018 Status changed from recruiting to active, no longer recruiting.